You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

257 Results
Document
Guidelines and Advice
Oct 2023
The following information answers many of the questions primary care physicians commonly ask about the Screening Activity Report and the included...
Drug
Other Name(s): Sylvant®
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Palliative
Funding:
New Drug Funding Program
    Siltuximab - Multicentric Castleman’s Disease (MCD)
Mar 2025
Les programmes cliniques d’Action Cancer Ontario sont mis en œuvre en collaboration avec les cliniciens des Programmes régionaux de cancérologie en...

Pages